J. Trieu

发表

Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate‐risk prostate cancer at high risk of distant recurrence and cancer‐specific mortality

D. Song, P. Tran, C. Deville, 2018, The Prostate.

Direct T Cell Activation via CD40 Ligand Generates High Avidity CD8+ T Cells Capable of Breaking Immunological Tolerance for the Control of Tumors

T. Wu, C. Hung, Liangmei He, 2014, PloS one.

Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.

N. Vogelzang, M. Anderson, M. Chang, 2022, Clinical genitourinary cancer.

Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.

D. Song, P. Tran, C. Deville, 2018, Urologic oncology.

Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53

T. Wu, C. Hung, Liangmei He, 2013, PloS one.

Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

R. Roden, T. Wu, W. Huh, 2014, Clinical Cancer Research.

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma

O. Elemento, J. Mosquera, G. Sonpavde, 2022, British Journal of Cancer.

End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer

D. Song, P. Tran, C. Deville, 2016, Prostate Cancer and Prostatic Diseases.

Cancer Therapy : Preclinical Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Speci fi c CD 8 þ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFN g

R. Roden, T. Wu, W. Huh, 2014 .

Toll like receptor agonist imiquimod facilitates antigen-specific CD 8 + T cell accumulation in the genital tract leading to tumor control through interferon-γ

R. Roden, T. Wu, W. Huh, 2014 .